Biolase (BIOL) Misses Q2 EPS by 27c
Tweet
Share
E-mailGet Alerts BIOL Hot Sheet
Join SI Premium – FREE
Biolase (NASDAQ: BIOL) reported Q2 EPS of ($0.91), $0.27 worse than the analyst estimate of ($0.64). Revenue for the quarter came in at $12.2 million versus the consensus estimate of $10.63 million.
For earnings history and earnings-related data on Biolase (BIOL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Phillip Securities Reiterates Buy Rating on Sea Ltd. (SE)
- Brainstorm Cell Therapeutics (BCLI) Misses Q2 EPS by 6c
- Citius Pharmaceuticals (CTXR) Misses Q3 EPS by 37c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
